01 1PolyPeptide Group
01 1SEMAGLUTIDE
01 1Switzerland
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2021-10-14
Pay. Date : 2021-07-19
DMF Number : 36101
Submission : 2021-07-12
Status : Active
Type : II
20
Polypeptide Sa, based in Switzerland, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is SEMAGLUTIDE, with a corresponding US DMF Number 36101.
Remarkably, this DMF maintains an Active status since its submission on July 12, 2021, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of October 14, 2021, and payment made on July 19, 2021, indicating their dedication to facilitating drug approvals, Categorized as Type II
